Delcath Systems, Inc. (OTCMKTS:DCTHD) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

Delcath Systems (DCTHD) traded down $0.13 during trading on Tuesday, hitting $1.12. The stock had a trading volume of 417,696 shares, compared to its average volume of 78,739. Delcath Systems has a 1-year low of $0.96 and a 1-year high of $1,015.02.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at

A hedge fund recently raised its stake in Delcath Systems stock. Vanguard Group Inc. lifted its holdings in shares of Delcath Systems, Inc. (OTCMKTS:DCTHD) by 207.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,285,679 shares of the medical device company’s stock after buying an additional 866,838 shares during the period. Vanguard Group Inc. owned approximately 1.09% of Delcath Systems worth $253,000 at the end of the most recent quarter. Institutional investors and hedge funds own 7.97% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Delcath Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems Inc. and related companies with's FREE daily email newsletter.